Patents by Inventor Su Kyoung YOO

Su Kyoung YOO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12012619
    Abstract: An NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. The enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: June 18, 2024
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun Joong Kim, Hun-Dong Lee, Su-Kyoung Yoo, Dae Eun Cheong, Chul-Ho Yun, Hye-Ji Choi, Sang-Oh Ahn
  • Publication number: 20230340049
    Abstract: Provided is a method of preparing a circular permutation (CP)-based functional recombinant human-derived fibroblast growth factor 7 and a use thereof. The fibroblast growth factor 7 to which a circular permutation is applied (CP-hFGF7115-114) is independently expressed in a host cell, such that soluble overexpression of the fibroblast growth factor 7 may be induced without causing problems according to the related art, such as lower expression level and stability compared to those of a wild-type hFGF7 protein and amino acid changes in a process of removing a fusion tag.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 26, 2023
    Inventors: Geun-Joong KIM, Hye-Ji CHOI, Dae-Eun CHEONG, Su-Kyoung YOO, Hanui LEE
  • Publication number: 20230143972
    Abstract: An NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. The enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 11, 2023
    Inventors: Geun Joong KIM, Hun-Dong LEE, Su-Kyoung YOO, Dae Eun CHEONG, Chul-Ho YUN, Hye-Ji CHOI, Sang-Oh AHN
  • Patent number: 11608366
    Abstract: A recombinant vector according to an embodiment of the present invention may produce fibroblast growth factor 19 (FGF19) having enhanced solubility. The synonymous codon substitution variant fibroblast growth factor 19 (scvhFGF19) and chaperone ?ssDsbC may be simultaneously and independently expressed in a host cell into which the recombinant vector is introduced, thereby it is possible to overexpress the fibroblast growth factor 19 in a soluble state.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: March 21, 2023
    Assignees: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY, KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY
    Inventors: Geun Joong Kim, Hye Ji Choi, Dae Eun Cheong, Su Kyoung Yoo, Dong Hyun Lee, Jae Hong Park, Jung Hyun Lee, Hyung Soon Yim, Young Jun An, Kyeong Won Lee
  • Publication number: 20220267742
    Abstract: The present invention relates to an NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. In the present invention, the enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.
    Type: Application
    Filed: March 1, 2021
    Publication date: August 25, 2022
    Inventors: Geun Joong KIM, Hun-Dong LEE, Su-Kyoung YOO, Dae Eun CHEONG, Chul-Ho YUN, Hye-Ji CHOI, Sang-Oh AHN
  • Patent number: 11236309
    Abstract: A recombinant vector according to an embodiment of the present invention may be used for producing a reconstituted cytochrome P450 oxygenase-reductase fusion protein. Oxygenase and reductase may be independently expressed in a host cell into which the recombinant vector is introduced, and then may be fused with a split intein so that it is possible to increase the heme content contained in the active site of the oxygenase and improve enzyme activity and stability.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: February 1, 2022
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun Joong Kim, Chul Ho Yun, Dae Eun Cheong, Su Kyoung Yoo, Hye Ji Choi, Thien Kim Le
  • Publication number: 20210355182
    Abstract: A recombinant vector according to an embodiment of the present invention may produce fibroblast growth factor 19 (FGF19) having enhanced solubility. The synonymous codon substitution variant fibroblast growth factor 19 (scvhFGF19) and chaperone ?ssDsbC may be simultaneously and independently expressed in a host cell into which the recombinant vector is introduced, thereby it is possible to overexpress the fibroblast growth factor 19 in a soluble state, due to when not utilizing tags such as an existing fusion partner there is no change in the amino acid, which is a problem generated in the removal process.
    Type: Application
    Filed: August 19, 2020
    Publication date: November 18, 2021
    Inventors: Geun Joong KIM, Hye Ji CHOI, Dae Eun CHEONG, Su Kyoung YOO, Dong Hyun LEE, Jae Hong PARK, Jung Hyun LEE, Hyung Soon YIM, Young Jun AN, Kyeong Won LEE
  • Publication number: 20210355456
    Abstract: A recombinant vector according to an embodiment of the present invention may be used for producing a reconstituted cytochrome P450 oxygenase-reductase fusion protein. Oxygenase and reductase may be independently expressed in a host cell into which the recombinant vector is introduced, and then may be fused with a split intein so that it is possible to increase the heme content contained in the active site of the oxygenase and improve enzyme activity and stability.
    Type: Application
    Filed: August 17, 2020
    Publication date: November 18, 2021
    Inventors: Geun Joong KIM, Chul Ho YUN, Dae Eun CHEONG, Su Kyoung YOO, Hye Ji CHOI, Thien Kim Le